# **IJARSCT**



International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

Volume 2, Issue 5, May 2022

# **Chrono-Pharmaceutical: Future of Pharmaceutics**

## Snehal S More<sup>1</sup>, Sanket S Gadhe<sup>2</sup>, Shrikant K Ainor<sup>2</sup>, Shriram K Thorat<sup>3</sup>

Department of Quality Assurance Techniques, Siddhant College of Pharmacy, Pune, Maharashtra, India<sup>1</sup> Department of Pharmaceutics, Sanjivani, College of Pharmaceutical Education & Research, Kopargaon<sup>2</sup> Department of Pharmaceutics, AISSMS College of Pharmacy, Pune, Maharashtra, India<sup>3</sup>

Abstract: The term "chrono-pharmaceutics" is a combination of chronobiology and pharmaceutics. In chronobiology, biological rhythms (circadian, ultradian and infradian) and their mechanisms are discussed. Circadian rhythms, which last about one day, are themost studied type of biological rhythm. The term "circadian" comes from the Latin words for about (circa) a day (Diem). Body rhythms of shorter duration are termed "ultradian" 6'hr (more than one cycle per 24 h). Body rhythms that are longer than 24 h are "infradian" (less than one cycle per 24 h) rhythm. Pharmaceutics is an area of biomedical and pharmaceutical sciences that deals with the design and evaluation of pharmaceutical dosage forms (or drug delivery systems) to assure their safety, effectiveness, quality and reliability. Coordination of biological rhythms with medical treatment is called chrono-therapy.

**Keywords:** Chrono-pharmaceutics, chrono-therapy, circadian, chrono-theranostics.

#### REFERENCES

- [1]. B.S. Shastry, Genetic diversity and new therapeutic concepts, J. Hum. Genet. 50(2005) 321–328.
- [2]. B.S. Shastry, Pharmacogenetics and the concept of individualized medicine, Pharmacogenomics J. 6 (2006) 16–21.
- [3]. P. Schulz, T. Steimer, Neurobiology of circadian systems, CNS Drugs 23 (Suppl 2)(2009) 3–13.
- [4]. C.R. Jones, S.S. Campbell, S.E. Zone, F. Cooper, A. DeSano, P.J. Murphy, B. Jones, L.Czajkowski, L.J. Ptacek, Familial advanced sleep-phase syndrome: a short-periodcircadian rhythm variant in humans, Nat. Med. 5 (1999) 1062–1065.
- [5]. S. Ohdo, S. Koyanagi, H. Suyama, S. Higuchi, H. Aramaki, Changing the dosingschedule minimizes the disruptive effects of interferon on clock function, Nat. Med. 7 (2001) 356–360.
- [6]. B. Staels, When the clock stops ticking, metabolic syndrome explodes, Nat. Med.12 (2006) 54–55 discussion 55.
- [7]. B.B.C. Youan (Ed.), Chronopharmaceutics: Science and Technology for BiologicalRhythm Guided Therapy and Prevention of Diseases, John Wiley & Sons, Hoboken, NJ, USA, 2009.
- [8]. D.A. Oren, T.A. Wehr, Hypernyctohemeral syndrome after chronotherapy fordelayed sleep phase syndrome, N Engl J. Med. 327 (1992) 1762.
- [9]. Smolensky, M. H. and Labrecque, G.: Chronotherapeutics. Pharmaceutical News, 4: 10–16 (1997).
- [10]. Ohdo, S., Koyanagi, S., Suyama, H., Higuchi, S. and Aramaki, H.: Changing the dosing schedule minimizes the disruptive eŠects of interferon on clock function. Nature Med., 7: 356–360 (2001).
- [11]. Youan, B.-B.C.: Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery? J. Control. Rel., 98: 337–353 (2004).
- [12]. FDA, Electronic Orange Book, Washington, DC, Administration, F.a. D., 2003.
- [13]. B.B.C. Youan, Chronopharmaceutics: gimmick or clinically relevant approach todrug delivery, J. Control. Release 98 (2004) 337–353.
- [14]. G.D. Rosenberg, D.J. Simmons, Rhythmic dentinogenesis in the rabbit incisor:circadian, ultradian and infradian periods, Calcif. Tissue Int. 32 (2006) 29–44.
- [15]. M.H. Smolensky, N.A. Peppas, Chronobiology, drug delivery and chronopharmaceutics, Adv. Drug Deliv. Rev. 59 (2007) 828–851.

DOI: 10.48175/IJARSCT-4028

[16]. B. Lemmer, Chronobiology, drug-delivery and chronotherapeutics, Adv. DrugDeliv. Rev. 59 (2007) 825–827.

# **IJARSCT**



### International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

## Volume 2, Issue 5, May 2022

- [17]. T. Bussemer, N.A. Peppas, R. Bodmeier, Evaluation of the swelling, hydration andrupturing properties of the swelling layer of a rupturable pulsatile drug deliverysystem, Eur. J. Pharm. Biopharm. 56 (2003) 261–270.
- [18]. A. Reinberg, Clinical chronopharmacology. An experimental basis for chronotherapy,in: A. Reinberg, M.H. Smolensky (Eds.), Biological Rhythms and Medicine, Cellular, Metabolic, Physiopathologic and Pharmacologic Aspects, Springer, Heidelberg, 1983, pp. 211–263.
- [19]. A.E. Reinberg, Concepts of circadian chronopharmacology, in: Temporal Controlof Drug Delivery, W.J.M. Hrushesky, R. Langer, F. Theeuwes (Eds.), Ann. N. Y.Acad. Sci., vol. 618, 1991, pp. 102–115.
- [20]. F. Pozzi, P. Furlani, A. Gazzaniga, S.S. Davis, I.R. Wilding, The time clock system: anew oral dosage form for fast and complete release of drug after a predeterminedlag time, J. Control. Release 31 (1994) 99–108.
- [21]. B.B.C. Youan, Chronopharmaceutical drug delivery systems: hurdles, hype orhope? Adv. Drug Deliv. Rev. 62 (2010) 898–903.
- [22]. Michael H. Smolensky, Nicholas A. Peppas, Chronobiology, drug delivery, and chronotherapeutics, Advanced Drug Delivery Reviews 59 (2007) 828–851

DOI: 10.48175/IJARSCT-4028